首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Esmo open

缩写:

ISSN:N/A

e-ISSN:2059-7029

IF/分区:8.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2013
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
F Bertucci,P Finetti,L Mescam et al. F Bertucci et al.
Background: Soft tissue sarcomas (STSs) are aggressive and heterogeneous tumors with few efficient systemic therapies. Antibody-drug conjugates (ADCs) represent an emerging therapeutic option in oncology. Their efficacy i...
A Reichinger,A Friedrich,T Lentner et al. A Reichinger et al.
Background: NALIRIFOX, a triplet chemotherapy regimen combining nanoliposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin, demonstrated superior survival outcomes versus gemcitabine plus nab-paclitaxel in the N...
L F C de Almeida,L F Leite,V O C Filho et al. L F C de Almeida et al.
Background: Adding cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy (ET) is considered the first-line treatment of advanced HR-positive/HER2-negative breast cancer. However, with the recent approval o...
S Morganti,R J Kusmick,M E Hughes et al. S Morganti et al.
Background: Sacituzumab govitecan (SG) is an anti-trop2 antibody-drug conjugate (ADC) approved for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). However, data on effectiveness of...
U Košir,A Totovina,D Stark et al. U Košir et al.
In 2022, according to the Global Cancer Observatory, >115 000 adolescents and young adults (AYAs; aged 15-39 years) were diagnosed with cancer across Europe. Despite their unique biological and psychosocial needs, AYAs face disparity of acc...
C Chen,H A Mejbel,T Pathak et al. C Chen et al.
Background: Gastrointestinal (GI) cancers (including esophagus, stomach, colon, rectum, pancreas and liver) account for more than one-quarter of all cancer diagnoses and 35% of cancer-related fatalities worldwide. Quantif...
K Yamamoto,Y Owaki,I Nakayama et al. K Yamamoto et al.
Background: Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), plus chemotherapy has become a standard treatment for CLDN18.2-positive advanced gastric cancer and is frequently associated with early-on...
Y Y Janjigian,A Kawazoe,J Xu et al. Y Y Janjigian et al.
Background: In the primary analysis of the randomized phase III KEYNOTE-811 trial (NCT03615326), pembrolizumab plus trastuzumab and chemotherapy improved progression-free survival and overall survival versus placebo plus ...
E Seguí,F Brasó-Maristany,T Pascual et al. E Seguí et al.
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, yet responses vary across cancer types, highlighting the need for reliable pan-cancer biomarkers. Prior retrospective studies...